Beam Therapeutics

NEWS

Business

Top 20 Life Science Startups to Watch in 2019

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.

November 6, 2018

·

12 min read

·

AWARDS

JOBS

IN THE PRESS

Business

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases

January 10, 2022

·

10 min read

Business

Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases

June 30, 2021

·

7 min read

Genetown

Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies

June 15, 2020

·

10 min read

Deals

Beam Therapeutics Announces Closing of Initial Public Offering

February 11, 2020

·

2 min read

Deals

Beam Therapeutics Announces Pricing of Initial Public Offering at $17.00 per share

February 11, 2020

·

2 min read

Genetown

Beam Therapeutics Announces Multiple Scientific Advances in its Base Editing Technology Platforms

February 11, 2020

·

5 min read

Deals

Beam Therapeutics Announces Pricing of Initial Public Offering at $17.00 per share.

February 5, 2020

·

2 min read

Business

Beam Therapeutics Promotes Giuseppe Ciaramella, Ph.D., to President and Chief Scientific Officer

January 24, 2020

·

2 min read

Drug Development

Beam Therapeutics Presents Preclinical Data for Complementary Base Editing Approaches for Hemoglobinopathies at ASH 2019

December 8, 2019

·

3 min read

Drug Development

Beam Therapeutics to Present New Preclinical Data on Base Editing Programs for Hemoglobinopathies at ASH 2019

November 21, 2019

·

1 min read